Aktuelle News
News Funktionen
Weitere Funktionen
13 März 2024
Kuros Biosciences AG
Kuros reports 163% growth in direct MagnetOs sales and 153% increase in total medical device sales for the full year 2023
8 März 2024
Kuros Biosciences AG
Kuros Biosciences to Report Full Year Financial Results for 2023 and Provide Corporate Update
1 Februar 2024
Kuros Biosciences AG
Kuros Biosciences to Present at the CG 2024 Musculoskeletal Conference
31 Januar 2024
Kuros Biosciences AG
Kuros Biosciences Receives US FDA 510K Clearance for MagnetOs Granules for Interbody Use and Regulatory Clearance of MagnetOs Granules and MagnetOs Putty in New Zealand
4 Januar 2024
Kuros Biosciences AG
Kuros Biosciences Announces Three Advancements Related to its MagnetOsTM Portfolio Including Impressive Fusion Data from MAXA Prospective Randomized Clinical Trial and Two 510(k) Clearances from FDA
27 Dezember 2023
Kuros Biosciences AG
Kuros Biosciences Announces Results from Two Prospective Randomized Clinical Trials: STRUCTURE and MAXA
28 November 2023
Kuros Biosciences AG
Kuros Biosciences Receives FDA Clearance for Use of MagnetOs in Interbody Spinal Cages
12 Oktober 2023
Kuros Biosciences AG
Kuros reports a 150% increase in direct MagnetOs sales in the first nine months of 2023 and announces changes within the Executive Management
9 August 2023
Kuros Biosciences AG
Kuros Biosciences Reports Results for First Half 2023
13 Juli 2023
Kuros Biosciences AG
Kuros Biosciences Announces Completion of Enrollment in the Fibrin-PTH Phase 2 Trial
8 Mai 2023
Kuros Biosciences AG
Annual General Meeting of Kuros Biosciences approves all resolutions
27 April 2023
Kuros Biosciences AG
Kuros reports 168% increase in direct MagnetOs sales in the first quarter of 2023
15 März 2023
Kuros Biosciences AG
Kuros Biosciences reports results for the full year 2022
21 Februar 2023
Kuros Biosciences AG
Kuros Biosciences Announces Publication of Supportive Osteoimmunology Data for MagnetOs Bone Graft
16 Februar 2023
Kuros Biosciences AG
Kuros Biosciences Announces Changes to Executive Management Team
23 November 2022
Kuros Biosciences AG
Kuros Biosciences Completes Enrollment of Randomized Stage of Phase 2 Trial for Fibrin-PTH
2 November 2022
Kuros Biosciences AG
Kuros Biosciences completes enrolment in Level 1 clinical study of MagnetOs Granules
26 Oktober 2022
Kuros Biosciences AG
Kuros reports 73% increase in MagnetOs sales in first nine months of 2022
19 Oktober 2022
Kuros Biosciences AG
Kuros Biosciences awarded 2022 Spine Technology Award for MagnetOs Flex Matrix by Orthopedics This Week
11 Oktober 2022
Kuros Biosciences AG
Kuros Biosciences to present positive clinical data for MagnetOs at NASS 2022 Annual Meeting
Kuros Biosciences AG
Kuros Biosciences to present positive clinical data for MagnetOs at NASS 2022 Annual Meeting
3 Oktober 2022
Kuros Biosciences AG
Kuros Biosciences Appoints Chris Fair as Chief Operating Officer
15 September 2022
Kuros Biosciences AG
Kuros Biosciences announces successful CHF 6.0 million private placement
23 August 2022
Kuros Biosciences AG
Kuros Biosciences’ MagnetOs Bone Graft Successfully Achieves Three Key Milestones
9 August 2022
Kuros Biosciences AG
Kuros Biosciences reports results for the first six months of 2022
8 Juni 2022
Kuros Biosciences AG
Annual General Meeting of Kuros Biosciences approves all resolutions
2 Juni 2022
Kuros Biosciences AG
Kuros Biosciences: Completion of the acquisition of Checkmate Pharmaceuticals by Regeneron Pharmaceuticals triggers a $5 million milestone payment
31 Mai 2022
Kuros Biosciences AG
Kuros Biosciences announces favorable preliminary results of MagnetOs as standalone alternative to autograft in first randomized controlled trial
18 Mai 2022
Kuros Biosciences AG
Kuros Biosciences announces commercial launch of MagnetOs Easypack Putty in the U.S.
27 April 2022
Kuros Biosciences AG
Kuros Biosciences continues strong commercial roll-out of MagnetOs bone graft